APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 143 filers reported holding APELLIS PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,600,034 | +126.7% | 68,350 | +442.8% | 0.02% | +150.0% |
| Q2 2023 | $1,147,040 | +176367.7% | 12,591 | +27.7% | 0.01% | +60.0% |
| Q1 2023 | $650 | +27.7% | 9,860 | +0.1% | 0.01% | +25.0% |
| Q4 2022 | $509 | -99.9% | 9,848 | -0.2% | 0.00% | -33.3% |
| Q3 2022 | $657,000 | +56.1% | 9,863 | +6.1% | 0.01% | +50.0% |
| Q2 2022 | $421,000 | +343.2% | 9,300 | +400.0% | 0.00% | +300.0% |
| Q1 2022 | $95,000 | +14.5% | 1,860 | -9.3% | 0.00% | 0.0% |
| Q4 2021 | $83,000 | -49.1% | 2,050 | -58.6% | 0.00% | 0.0% |
| Q3 2021 | $163,000 | -12.4% | 4,952 | +67.9% | 0.00% | 0.0% |
| Q2 2021 | $186,000 | +46.5% | 2,950 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $127,000 | -24.9% | 2,950 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $169,000 | +119.5% | 2,950 | +15.7% | 0.00% | 0.0% |
| Q3 2020 | $77,000 | +327.8% | 2,550 | +363.6% | 0.00% | – |
| Q2 2020 | $18,000 | +20.0% | 550 | 0.0% | 0.00% | – |
| Q1 2020 | $15,000 | – | 550 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |